Renal autotransplant (RA) may be used in select patients with chronic renal pain after all other means of pain control have been exhausted. Because this procedure is relatively rare, and because the indications and outcomes are subjective, success rates are difficult to assess. We aimed to determine the effectiveness of RA in the management of refractory chronic kidney pain.
INTRODUCTION AND OBJECTIVES:
Renal autotransplant (RA) may be used in select patients with chronic renal pain after all other means of pain control have been exhausted. Because this procedure is relatively rare, and because the indications and outcomes are subjective, success rates are difficult to assess. We aimed to determine the effectiveness of RA in the management of refractory chronic kidney pain.
METHODS: Chart review was completed of all patients who underwent RA at our institution between 2004 and 2018 for an indication of chronic pain. Demographics, medical and surgical history, operative details, and complications were recorded. Patients were mailed an information sheet and those who agreed to participate completed a validated Brief Pain Inventory (BPI) that included assessment of pain and analgesic use. Univariate analysis was performed, and a linear regression model was fit to each univariate model. RESULTS: A total of 98 patients underwent 114 RA, of which 31 were completed for a primary indication of chronic pain. Pre and postoperative pain scores and medications were assessed via the BPI. The average age at surgery was 34 (range from 16 to 48 years). The mean change in average pain was -3.3 points. There was improvement in the average pain scores after 22 (71%) RA, no change after 6 (19.4%), and worse pain after 3 (<1%). Complete discontinuation of opioids was achieved in 21 patients, and 8 patients continued opioid medications at a lower dosage than prior to surgery. Postoperative pain medication information was not available for one patient. On univariate analysis ipsilateral renal surgery and recent renal function were significantly associated with change in mean pain score. The improvement in pain score for patients without a history of prior surgery on the same kidney was 3.31 units better than for those with a history of surgery on the same kidney (SE 1.17, p[0.009) . Similarly, a lower creatinine at most recent follow up was associated with greater improvement in average pain score, by 4.02 units per each 1.0 mg/dL difference in creatinine (SE 1.85, p [ 0.039). Preoperative psychiatry evaluation, successful preoperative pain block, operative time, gender, age, pain etiology, and use of ureteral stenting were not predictive of an improvement in postoperative pain score.
CONCLUSIONS: We describe 31 RA completed at one institution for an indication of refractory chronic severe renal pain. The majority of patients had improvement in pain scores postoperatively, with 70% reporting discontinuation of all opioid medications. Higher postoperative creatinine and history of ipsilateral renal surgery were associated with less improvement in pain.
Source of Funding: None

PD54-03 RECELLULARIZATION OF RAT KIDNEY SCAFFOLD VASCULATURE WITH HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS
Adarsh Manjunath*, Katherine Hekman, Kyle Koss, Christina Im, Jason Wertheim, Chicago, IL INTRODUCTION AND OBJECTIVES: Bioartificial replacement renal tissues may alleviate the shortage of transplantable kidneys and may minimize the risk of rejection. In order to measure the durability of stem cell derived tissues in vivo, an animal model must be developed in which a kidney scaffold can be sustained by the flow of recipient blood. However, activation of circulating platelets occurs once exposed to type IV collagen in the scaffold's vasculature, resulting in blood clots and graft failure. We hypothesize that scaffold vascular recellularization can be optimized by altering endothelial cell number, the route of recellularization, and perfusion rate and time within a bioreactor.
METHODS: Kidneys were extracted from donor rats and a series of weak detergents administered into the organ via the renal artery. In a 26-hour protocol, these weak detergents removed all native cells while leaving the extracellular matrix intact. Human umbilical vein endothelial cells were cultured from 5 to 20 million in quantity and injected via syringe pump into these kidney scaffolds via the artery, vein, or both artery and vein. These recellularized scaffolds were perfused in a bioreactor, a tissue culture device that pumps cell culture media through the scaffold, at various perfusion rates. Time within the bioreactor varied from 2 to 7 days. Resazurin assays were performed to quantify cell proliferation within the scaffolds while in the bioreactor. Scaffolds were then sectioned and immunostained for CD31, an endothelial cell marker, and elastin, a marker for blood vessels.
RESULTS: Results from the resazurin assay and immunostaining indicate the greatest coverage of the vasculature was seen with injection of 10 million endothelial cells, injection via the artery, perfusion started at 0.5 mL/minute and incrementally increased up to 4 mL/minute within 24 hours, and 2 days within the bioreactor (Figure 1) .
CONCLUSIONS: Altering several variables can optimize recellularization of the kidney scaffold vasculature. This will ultimately allow us to use a synthetic heparin derivative linked to a collagen binding peptide, with the goal of preventing clots and graft failure, to cover any exposed type IV collagen in the endothelial system prior to transplantation into recipient rats.
Source of Funding: Hartwell Foundation Grant
PD54-04 MANAGEMENT OF END-STAGE RENAL DISEASE PATIENTS DIAGNOSED WITH ACTIVE SURVEILLANCE-ELIGIBLE PROSTATE CANCER DURING PRE-TRANSPLANTATION WORK-UP: A DECISION ANALYSIS
Uwe Bieri, Kerstin Huebel, Harald Seeger, Zurich, Switzerland; Girish S. Kulkarni, Toronto, Canada; Tullio Sulser, Thomas Hermanns, Marian S. Wettstein*, Zurich, Switzerland INTRODUCTION AND OBJECTIVES: The general rule that every active malignancy is an absolute contraindication for renal transplantation (RT) is challenged by low-risk prostate cancer (PC), a malignancy nowadays mostly managed by active surveillance (AS) instead of definitive treatment (DT) due to its low risk of metastatic progression. Therefore, treatment teams often face the difficult task to balance the benefits of an early RT against the remaining risk of tumor progression. The aim of the current study was to compare the quality-adjusted life expectancy of different management strategies in patients diagnosed with AS-eligible PC during the pre-transplantation work-up.
METHODS: We developed a 7-state Markov microsimulation model and simulated the following 4 management strategies in a sampled cohort of 100'000 males: ( 
